CNTA
Centessa PharmaceuticalsCNTA
CNTA
About: Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
Employees: 75
0
Funds holding %
of 7,363 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 6 [Q3] → 12 (+6) [Q4]
73% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 15
20% more capital invested
Capital invested by funds: $1.74B [Q3] → $2.08B (+$342M) [Q4]
11% more funds holding
Funds holding: 103 [Q3] → 114 (+11) [Q4]
9.7% more ownership
Funds ownership: 84.66% [Q3] → 94.36% (+9.7%) [Q4]
5% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 37
97% less call options, than puts
Call options by funds: $117K | Put options by funds: $3.69M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$27
64%
upside
Avg. target
$27
64%
upside
High target
$27
64%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Morgan Stanley Jeffrey Hung 57% 1-year accuracy 16 / 28 met price target | 64%upside $27 | Overweight Assumed | 7 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
5 days ago
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting
BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that data from the Phase 1 clinical trial of ORX750, an investigational novel highly potent and selective OX2R agonist being progressed for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), will be presented in a poster session at the American Academy of Neurology (AAN) 2025 Annual Meeting being held April 5-9, 2025, in San Diego, CA. ORX750 is being evaluated in an ongoing Phase 2a clinical trial (CRYSTAL-1) in participants with NT1, NT2 and IH.
Neutral
GlobeNewsWire
2 months ago
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer
BOSTON and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today announced the appointment of Stephen Kanes MD PhD, as Chief Medical Officer (CMO). Dr. Kanes is a neuropsychiatrist, with a career in neuroscience, clinical psychiatry, and neuroscience drug development spanning more than 30 years.
Positive
Seeking Alpha
2 months ago
Centessa: Shift In Focus With ORX750 Development Continues To Pay Off
Centessa Pharmaceuticals shelved its SerpinPC candidate, which was being used to treat patients with Hemophilia B; Established net savings of $200 million because of this move. Positive interim and final analysis obtained from phase 1 study, using ORX750 for acutely sleep-deprived healthy volunteers; Positive outcome in terms of MWT and KSS efficacy measures. Results from several cohorts of phase 2a study using ORX750 to treat patients with NT1, NT2 and IH expected in 2025.
Neutral
GlobeNewsWire
3 months ago
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
BOSTON and LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients, today reported financial results for the third quarter ended September 30, 2024, and provided a business update.
Positive
MarketBeat
5 months ago
Wake Up to This Biotech Stock That Still Has Big Potential Upside
Centessa Pharmaceuticals NASDAQ: CNTA is a biotechnology stock that has nearly doubled its value so far this year, and its run may not be over. Analysts at Morgan Stanley have just massively raised their price target for the company.
Neutral
GlobeNewsWire
5 months ago
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
Late-breaking poster presentation of non-human primate (NHP) data support ORX142 as novel drug candidate for the treatment of excessive daytime sleepiness (EDS) in select neurological, neurodegenerative, and psychiatric disorders
Neutral
GlobeNewsWire
5 months ago
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
BOSTON and LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an upsized underwritten public offering of 15,254,237 of American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $14.75 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $225 million, before deducting underwriting discounts and commissions and offering expenses payable by Centessa. All ADSs sold in the offering were offered by Centessa. The offering is expected to close on or about September 16, 2024, subject to customary closing conditions. Centessa has also granted the underwriters a 30-day option to purchase up to an additional 2,288,135 ADSs at the public offering price, less underwriting discounts and commissions.
Neutral
GlobeNewsWire
5 months ago
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
BOSTON and LONDON, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $150 million of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of ADSs offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Neutral
GlobeNewsWire
5 months ago
Nxera Pharma's Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
Tokyo, Japan and Cambridge, UK, 11 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – notes the announcement by Centessa Pharmaceuticals on 10 September 2024 reporting positive interim clinical data from its Phase 1 clinical trial with ORX750 in acutely sleep-deprived healthy volunteers. The full announcement from Centessa can be found by clicking here .
Positive
Investors Business Daily
6 months ago
Centessa Rockets To Three-Year High On $5 Billion Narcolepsy Opportunity
Centessa has a potential blockbuster narcolepsy treatment on its hands, an analyst said Tuesday as the biotech stock surged on test results.
Charts implemented using Lightweight Charts™